What is the 13F Pro Quality Score for CLYM?

13F Pro ranks Climb Bio, Inc. (CLYM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CLYM's current score at https://13fpro.ai/research/CLYM (free sign-up required for the full ranking).

Which hedge funds own the most CLYM stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CLYM include RA CAPITAL MANAGEMENT, L.P., MPM BioImpact, BRAIDWELL. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/CLYM as soon as new 13F filings post.

Where does 13F Pro source CLYM data?

All Climb Bio, Inc. fundamentals and ownership data come directly from SEC EDGAR. Climb Bio, Inc. files with the SEC under CIK 1768446. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CLYM in?

Climb Bio, Inc. (CLYM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CLYM research updated on 13F Pro?

CLYM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Climb Bio, Inc.(CLYM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1768446 CLYM stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

CLYM Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Climb Bio, Inc. (CLYM), a Healthcare sector company. CLYM is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Climb Bio, Inc. reports net income of $-13.7M, free cash flow of $-14.4M. Top institutional holders of CLYM by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., MPM BioImpact, BRAIDWELL, based on the most recent SEC filings. CLYM trades on the Nasdaq exchange and files with the SEC under CIK 1768446. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CLYM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Climb Bio, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-13.7M

Free Cash Flow

Q1 2026

$-14.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+19.0% YoY

$-59.9MFY 2025

FY20 $-20.7MFY23 $-35.1MFY24 $-73.9MFY25 $-59.9M

Operating Income

+17.2% YoY

$-67.9MFY 2025

FY20 $-20.9MFY23 $-40.3MFY24 $-82.0MFY25 $-67.9M

EPS (Diluted)

+42.5% YoY

$-0.88FY 2025

FY20 —FY23 $-1.30FY24 $-1.53FY25 $-0.88

Total Assets

-22.8% YoY

$167.7MFY 2025

FY20 $24.6MFY23 $110.5MFY24 $217.2MFY25 $167.7M

Op. Cash Flow

-249.3% YoY

$-54.4MFY 2025

FY20 $-14.1MFY23 $-20.6MFY24 $-15.6MFY25 $-54.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2020	FY 2019
Net Income	$-59.9M +19.0%	$-73.9M -110.4%	$-35.1M -69.9%	$-20.7M	—
Operating Income	$-67.9M +17.2%	$-82.0M -103.6%	$-40.3M -92.5%	$-20.9M	—
EPS (Diluted)	$-0.88 +42.5%	$-1.53 -17.7%	$-1.30	—	—
Total Assets	$167.7M -22.8%	$217.2M +96.6%	$110.5M +348.5%	$24.6M	—
Operating Cash Flow	$-54.4M -249.3%	$-15.6M +24.5%	$-20.6M -46.1%	$-14.1M	—

AI Insight: CLYM Financial Trends

Climb Bio is a pre-revenue cash burner: equity has eroded from $222M to $148M over seven quarters with no revenue in sight.

• Equity has declined steadily from $222M in Q2 2024 to $148M in Q1 2026, a cumulative erosion of $74M.

• Operating cash outflows accelerated to -$16M in Q4 2025 from -$1M in Q2 2024, signaling rising cash burn.

• Net loss moderated to -$14M in Q1 2026 versus the -$55M spike in Q2 2024, though that spike appears non-recurring.

⚠ At the Q1 2026 burn rate (~$14M/quarter), remaining equity of $148M implies roughly 10 quarters of runway.

⚠ Zero revenue across all eight quarters; any delay in pipeline milestones accelerates equity depletion risk.

⚠ No debt reported, but continued losses may force dilutive equity raises or debt issuance to sustain operations.

AI Insight: CLYM Ratio Trends

CLYM remains deeply unprofitable with no margin data available and return metrics deteriorating sharply in Q4 2025.

• ROE swung from -15.9% in Q4 2024 to -43.7% in Q4 2025, signaling worsening losses year-over-year.

• ROIC deteriorated from -20.6% in Q4 2024 to -48.1% in Q4 2025, the worst quarterly reading in the dataset.

• OpMargin, NPM, and D/E are entirely absent across all periods, limiting visibility into cost structure and leverage.

⚠ ROIC hit -48.1% in Q4 2025 — deepest destruction in the series — monitor whether Q1 2026's -41.1% marks a genuine recovery.

⚠ TTM ROA of -34.6% vs. Q1 2026 quarterly ROA of -36.0% suggests no meaningful improvement in asset efficiency.

Get alerted when CLYM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Climb Bio, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CLYM

RA CAPITAL MANAGEMENT, L.P.
$77.4M11,300,939 sh
MPM BioImpact LLC
$17.8M2,593,439 sh
BRAIDWELL LP
$10.5M1,529,675 sh
GREAT POINT PARTNERS LLC
$9.1M1,334,130 sh
MILLENNIUM MANAGEMENT LLC
$8.7M1,276,260 sh
VANGUARD CAPITAL MANAGEMENT LLC
$8.1M1,178,659 sh
Kynam Capital Management, LP
$6.9M1,003,341 sh
MARSHALL WACE, LLP
$5.3M773,123 sh
Affinity Asset Advisors, LLC
$4.8M700,000 sh
SILVERARC CAPITAL MANAGEMENT, LLC
$4.7M684,908 sh

Fund	Value	Shares
RA CAPITAL MANAGEMENT, L.P.	$77.4M	11,300,939
MPM BioImpact LLC	$17.8M	2,593,439
BRAIDWELL LP	$10.5M	1,529,675
GREAT POINT PARTNERS LLC	$9.1M	1,334,130
MILLENNIUM MANAGEMENT LLC	$8.7M	1,276,260
VANGUARD CAPITAL MANAGEMENT LLC	$8.1M	1,178,659
Kynam Capital Management, LP	$6.9M	1,003,341
MARSHALL WACE, LLP	$5.3M	773,123
Affinity Asset Advisors, LLC	$4.8M	700,000
SILVERARC CAPITAL MANAGEMENT, LLC	$4.7M	684,908

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CLYM on your watchlist

Track score changes the day Climb Bio, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CLYM a good stock to buy?

13F Pro's AI-powered analysis of Climb Bio, Inc. (CLYM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CLYM are available on the CLYM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CLYM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CLYM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Climb Bio, Inc.'s investment landscape.